AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 71 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $285,000 | -20.6% | 40,190 | +3.6% | 0.00% | -33.3% |
| Q2 2020 | $359,000 | +223.4% | 38,804 | +63.3% | 0.01% | +100.0% |
| Q1 2020 | $111,000 | -69.8% | 23,763 | -50.7% | 0.00% | +50.0% |
| Q4 2019 | $368,000 | -32.5% | 48,222 | -31.9% | 0.00% | -60.0% |
| Q3 2019 | $545,000 | +50.6% | 70,861 | +34.0% | 0.01% | +25.0% |
| Q2 2019 | $362,000 | +16.0% | 52,864 | +36.4% | 0.00% | +33.3% |
| Q1 2019 | $312,000 | -29.9% | 38,752 | -34.8% | 0.00% | -40.0% |
| Q4 2018 | $445,000 | -34.9% | 59,443 | -16.9% | 0.01% | -37.5% |
| Q3 2018 | $684,000 | +95.4% | 71,500 | +116.0% | 0.01% | +60.0% |
| Q2 2018 | $350,000 | +233.3% | 33,108 | +212.3% | 0.01% | +150.0% |
| Q1 2018 | $105,000 | +15.4% | 10,600 | -13.1% | 0.00% | -33.3% |
| Q1 2017 | $91,000 | – | 12,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |